

BrainChild Bio Closes \$116 Million Series A

Client News

September 8, 2026

Gunderson Dettmer represented BrainChild Bio in its \$116 million Series A financing. An undisclosed private family fund and foundation, aligned with BrainChild Bio's mission, led the financing round, with participation from the company's initial investor, Seattle Children's, and new investor WRF Capital.

Brainchild Bio, a kids-first, clinical-stage biotechnology company, is harnessing the power of CAR T cell technology to treat tumors in the central nervous system. The company will use the new capital to support its ILLUMINATE Phase 2 study, a pivotal clinical trial to evaluate BCB-276, the company's investigational B7-H3-targeted autologous CAR T cell therapy, for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and aggressive pediatric brainstem tumor with limited treatment options. The funding will also support the continued development of BCB-214, the company's triple-targeting CAR T cell therapy being advanced to initial clinical testing in glioblastoma.

"This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS brain tumors in children and adults," said Michael Jensen, MD, Founder and Chief Scientific Officer of BrainChild Bio, [in the announcement of the transaction](#). "Our team at BrainChild Bio is steadfast in its commitment to harness CAR T cell technology in CNS tumors and we are uniquely positioned to do so."

The Gunderson deal team was led by Tim Ehrlich and Tim Kulis and included Ryan Moser and Julie Bateman.

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Timothy J. Kulis

PARTNER

P +1 617 648 9236

Ryan J. Moser

ASSOCIATE

P +1 617 648 9244

Julie Bateman

ASSOCIATE

P +1 617 648 9201

Related Services

Early-Stage Company

Life Sciences

Private & Public Companies

Featured Insights

PUBLIC VENTURES

Glass Lewis Invites Comment on Proposed 'Four Perspectives' Proxy Voting Research Model

FIRM NEWS

Gunderson Dettmer Commemorates 2026 Hispanic Heritage Month

CLIENT NEWS

Leyden Labs Acquires RIGImmune

CLIENT NEWS

Savvy Wealth Raises \$100 Million Series C

CLIENT NEWS

Bluecore Energy Announces \$50 Million Seed Financing

CLIENT NEWS

Point72 Ventures and Spark Capital Co-Lead Stoke Space's \$1 Billion Series E

PUBLIC VENTURES

SEC Files Subpoena Enforcement Action Against ISS

CLIENT NEWS

Gunderson Dettmer Represents Addition and Lux Capital in Hugging Face Sale to NVIDIA for \$12.9 Billion

CLIENT NEWS

Harbert Growth Partners Leads Yardstik's \$30 Million Series B

FIRM NEWS

Massachusetts Lawyers Weekly Recognizes Gunderson Dettmer Partner Tim Ehrlich as a Go To Life Sciences Lawyer

CLIENT NEWS

Faro AI Announces \$37.3 Million Series B

CLIENT NEWS

Emerald AI Raises \$150 Million Series A at \$1.05 Billion Valuation